DED

EyeCare Partners’ Leadership and Clinical Research to be Showcased at American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
torsdag, maj 4, 2023
Surgery, Health, Science, Research, Optical, Dark, Partner, Eye drop, Ophthalmology, ASCRS, Varenicline, Telecanthus, Patient satisfaction, Ciclosporin, Patient experience, ECP, Presbyopia, Ageing, Randomness, Cataract, Legacy Devers Eye Institute, Wonderful, Manual, Refractive surgery, Endothelium, Ocular hypertension, American Society of Cataract and Refractive Surgery, Somatosensory system, Ketamine, Contact lens, Political moderate, Learning curve, Pilocarpine, DED, Retina, Midazolam, Phacoemulsification, Corneal neovascularization, Loteprednol, Immunosuppression, Physician, Pivotal, Society, Treatment, Rejuvenation, Veterinary medicine, Nursing, Hospital, Telescopic sight, Medical imaging, Pharmaceutical industry, Casino, PRK, Tacrolimus, LASIK, Creatinine, History, Patient

The annual meeting will take place May 5-8, 2023, in San Diego.

Key Points: 
  • The annual meeting will take place May 5-8, 2023, in San Diego.
  • The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning.
  • It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice.
  • “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners.

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

Retrieved on: 
onsdag, maj 3, 2023
DED, LSE, Refractive surgery, ASCRS, American Society of Cataract and Refractive Surgery, Telecanthus, Tufts Medical Center, MD, NCP, Immune tolerance, Cataract, Society, Pharmaceutical industry

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that two presentations will be given on OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023.

Key Points: 
  • LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that two presentations will be given on OK-101 at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023.
  • The Company is pleased that Pedram Hamrah, MD, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at New England Eye Center at Tufts Medical Center, a leading expert on corneal neuropathic pain and DED, will be presenting both papers at this ASCRS meeting in San Diego.
  • These presentations will cover pre-clinical and animal model data on OK-101 in treating DED and Neuropathic Corneal Pain (NCP).
  • Paper Title: OK-101, a Novel Chemerin Receptor Agonist, Decreased Clinical Signs and Symptoms and Improved Immune Tolerance in Dry Eye Mouse Model
    Paper Title: OK-101, a Novel Chemerin Receptor Agonist, Improves Neuropathic Corneal Pain in Ciliary Nerve Ligation Mouse Model

Optomec Showcases Latest Additive Manufacturing Print Heads at RAPID + TCT 2023

Retrieved on: 
tisdag, maj 2, 2023
Other Manufacturing, Hardware, Electronic Design Automation, Steel, Engineering, Technology, Semiconductor, Manufacturing, Medical device, Maintenance, Heart, Metal, 3D printing processes, DED, Defense, 3D, LDH, RAPID, Multimedia, Marketing, Additive, Printed electronics, Aerospace, AM, 3D printing, 3.1, Electronics

Optomec, a leading manufacturer of Additive Manufacturing machines for both 3D Printed Metal and Printed Electronics will showcase its latest print solutions for each technology at RAPID + TCT 2023.

Key Points: 
  • Optomec, a leading manufacturer of Additive Manufacturing machines for both 3D Printed Metal and Printed Electronics will showcase its latest print solutions for each technology at RAPID + TCT 2023.
  • For Printed Electronics customers, Optomec will announce its latest Aerosol Jet® print head which delivers a compact, low maintenance solution for production applications.
  • View the full release here: https://www.businesswire.com/news/home/20230502005991/en/
    The CS250 machine (left) for Metal Additive Manufacturing, and the Aerosol Jet HD2 machine (right) for Printed Electronics.
  • “We are pleased to be showcasing our latest production print solutions at RAPID this year.” said Mike Dean, VP of Marketing at Optomec.

Novaliq Announces Presentation of New Scientific Data on CyclASol® 0.1% (Cyclosporine Ophthalmic Solution) at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
tisdag, maj 2, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, DED, Refractive surgery, Therapy, Patient satisfaction, Safety, Efficacy, Cataract, ASCRS, American Society of Cataract and Refractive Surgery, Telecanthus, Prescription Drug User Fee Act, Oil, MD, Patient, PDUFA, Ciclosporin, FDA, Society, Treatment, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, LASIK

CyclASol® is the first water-free topical anti-inflammatory and immunomodulating ophthalmic solution, containing 0.1% cyclosporine.

Key Points: 
  • CyclASol® is the first water-free topical anti-inflammatory and immunomodulating ophthalmic solution, containing 0.1% cyclosporine.
  • CyclASol® is preservative-free and does not contain any oils or surfactants, which can be irritating and disturbing for the tear film.
  • CyclASol® is currently under regulatory review for the treatment of signs and symptoms of dry eye disease (DED).
  • “Dry eye is a very common ocular surface disease and has also an influence on patient satisfaction after LASIK or cataract surgery.

OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease

Retrieved on: 
tisdag, maj 2, 2023
DED, LSE, Dry eye syndrome, Inflammation, Trial of the century, Telecanthus, Acquisition, FDA, Safety, Pharmaceutical industry, Iver Johnson

“The initiation of this trial of topically applied OK-101 to treat dry eye disease marks a significant step for the company as we have been laser focused on moving this drug candidate into clinical trials over the last 18 months,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.

Key Points: 
  • “The initiation of this trial of topically applied OK-101 to treat dry eye disease marks a significant step for the company as we have been laser focused on moving this drug candidate into clinical trials over the last 18 months,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.
  • “Importantly, this first clinical study is designed to include pre-specified primary efficacy endpoints which are the hallmark of phase 3 registration trials, and the results from this trial are anticipated before the end of this year.
  • “Furthermore, positive results would allow us to expedite the program towards FDA approval by leveraging results from this phase 2 dry eye trial in lieu of one of the two required phase 3 trials needed to support U.S. marketing authorization.
  • A number of contributing factors can lead to this condition, including age, sex, certain medical conditions, reduced tear production and tear film dysfunction.

Palatin Technologies to Host Key Opinion Leader Webinar

Retrieved on: 
måndag, maj 1, 2023
PTN, DED, KOL, Osteopathic medicine in the United States, Philadelphia College of Osteopathic Medicine, CMO, Trial of the century, Telecanthus, Ophthalmology, Aqueous humour, Patient, Bremelanotide, Webcast, Research, Conference, NYSE, New Orleans, Pharmaceutical industry, Palatine

CRANBURY, N.J., May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a key opinion leader (KOL) webinar on May 8, 2023 at 11:00 a.m. ET.

Key Points: 
  • - Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET
    CRANBURY, N.J., May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a key opinion leader (KOL) webinar on May 8, 2023 at 11:00 a.m.
  • The webinar will be moderated by Carl Spana, Ph.D., President & CEO of Palatin, and feature Bruce C. Stouch, Ph.D. (Philadelphia College of Osteopathic Medicine) and George Ousler, M.S.
  • The KOL presentation will be followed by a question-and-answer session with Dr. Stouch, Mr. Ousler, Dr. Raizman and Palatin senior management.
  • To register for the webinar and participate in the webcast, please go to Palatin's website at www.palatin.com or click here .

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

Retrieved on: 
torsdag, april 27, 2023
PTN, Lead, DED, ARVO, Association for Research in Vision and Ophthalmology, Eye, Signs and symptoms, CMO, Inflammation, MS, Data analysis, MD, Patient, Political moderate, Bremelanotide, Signs, Clutch (eggs), Effectiveness, Poster, Research, Conference, NYSE, Safety, Pharmaceutical industry, Palatine, Ophthalmology

CRANBURY, N.J., April 27, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference. The authors of the poster are George W. Ousler, MS, Robert Jordan, and Carl Spana, Ph.D. Mr. Ousler is an employee of Ora, Inc. and Mr. Jordan and Dr. Spana are employees of Palatin Technologies. The poster was presented by George Ousler on April 26, 2023 at the ARVO conference in New Orleans. The poster is available on Palatin's website at www.palatin.com.

Key Points: 
  • The poster was presented by George Ousler on April 26, 2023 at the ARVO conference in New Orleans.
  • The PL9643 MELODY-1 Phase 3 study is expected to have topline data in the second half of 2023.
  • The poster presents data from a completed Phase 2 clinical trial and from the Lead In population of the ongoing Phase 3 MELODY-1 trial.
  • "PL9643's novel mechanism of action potentially protects the ocular surface from the damaging effects of inflammation and helps resolve ongoing inflammation."

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
onsdag, april 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays

Retrieved on: 
tisdag, april 11, 2023
DED, Therapy, Telecanthus, American Academy, American Academy of Ophthalmology, American Journal, Patient, SAN, Allergic conjunctivitis, Vision science, Quality control, Diagnosis, Immunoglobulin E, Pharmaceutical industry, Medical imaging, Lactoferrin, Biotechnology, Ophthalmology

SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the start of manufacturing of both its proprietary Ocular Immunoglobulin E (IgE) and Lactoferrin diagnostic assays to fulfill the orders placed by its commercialization partner. As is a standard manufacturing practice, AXIM has begun manufacturing three separate lots of each assay that will be used for an internal reproducibility study with the third lot available to ship to customers. AXIM’s current manufacturing capacity is up to 25,000 units per month.

Key Points: 
  • ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today the start of manufacturing of both its proprietary Ocular Immunoglobulin E (IgE) and Lactoferrin diagnostic assays to fulfill the orders placed by its commercialization partner.
  • Unlike other clinically available assays, AXIM’s tests are quantitative and measures actual levels of both IgE and Lactoferrin allowing doctors to monitor targeted therapeutics.
  • Low Lactoferrin levels indicate DED and depressed ocular immunity, which may represent an increased surgical risk and of contact lens intolerance.
  • AXIM aims to address this discrepancy with its ocular diagnostic solution portfolio, beginning with both its IgE and Lactoferrin assays.

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

Retrieved on: 
tisdag, april 4, 2023
Glaucoma, DED, CET, Q&A, DME, OCS, Diabetic retinopathy, Inflammation, Pain, Telecanthus, Webcast, Pecten oculi, BST, Pharmaceutical industry, MD

Furthermore, in the coming months, Oculis plans on initiating two Phase 2 studies with OCS-02, a topical anti-TNF alpha monoclonal antibody fragment, in DED and in chronic anterior uveitis.

Key Points: 
  • Furthermore, in the coming months, Oculis plans on initiating two Phase 2 studies with OCS-02, a topical anti-TNF alpha monoclonal antibody fragment, in DED and in chronic anterior uveitis.
  • During the event, Oculis’ management team will provide an overview of the Company’s key development and late-stage pipeline.
  • To access the live event by phone, please pre-register for the conference call here .
  • A replay of the webcast will be available for 30 days following the event.